In conclusion, this study conducted a comprehensive GWAS analysis to explore genetic predictors of 5-FU-based adjuvant therapy in intermediate-stage CRC patients, identifying GALNT14-rs62139523 and DNMBP-rs10786578 genotypes as potential predictors. This evidence concerns the gene DNMBP and colorectal carcinoma.